Prospective Grant of Exclusive License: Method of Treating or Preventing Cancer Using Radiosensitizing Agents, 77038-77039 [E6-21905]

Download as PDF jlentini on PROD1PC65 with NOTICES 77038 Federal Register / Vol. 71, No. 246 / Friday, December 22, 2006 / Notices Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Fungai F. Chanetsa, PhD., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3135, MSC 7770, Bethesda, MD 20892, 301–435– 1262, chanetsaf@csr.nih.gov. Name of Committee: Health of the Population Integrated Review Group, Cardiovascular and Sleep Epidemiology Study Section. Date: February 15–16, 2007. Time: 8:30 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Park Hotel, 8400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: J. Scott Osborne, PhD., MPH, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4114, MSC 7816, Bethesda, MD 20892, (301) 435–1782, osbornes@csr.nih.gov. Name of Committee: Risk, Prevention and Health Behavior Integrated Review Group, Psychosocial Development, Risk and Prevention Study Section. Date: February 15–16, 2007. Time: 8:30 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Victoria S. Levin, MSW, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3142, MSC 7759, Bethesda, MD 20892, (301) 435– 0912, levinv@csr.nih.gov. Name of Committee: Molecular, Cellular and Developmental Neuroscience Integrated Review Group, Neurotransporters, Receptors, and Calcium Signaling Study Section. Date: February 15–16, 2007. Time: 8:30 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015. Contact Person: Peter B. Guthrie, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4182, MSC 7850, Bethesda, MD 20892, (301) 435– 1239, guthriep@csr.nih.gov. Name of Committee: Cardiovascular Sciences Integrated Review Group, Electrical Signaling, Ion Transport, and Arrhythmias Study Section. Date: February 15–16, 2007. Time: 8:30 a.m. to 2 p.m. Agenda: To review and evaluate grant applications. Place: Doubletree Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Rajiv Kumar, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4122, VerDate Aug<31>2005 17:45 Dec 21, 2006 Jkt 211001 MSC 7802, Bethesda, MD 20892, (301) 435– 1212, kumarra@csr.nih.gov. Name of Committee: Center for Scientific Review Special emphasis Panel, Bioengineering Research Partnership. Date: February 16, 2007. Time: 8:30 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Bahia Hotel, 998 West Mission Bay Drive, San Diego, CA 92109. Contact Person: Behrouz Shabestari, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5106, MSC 7854, Bethesda, MD 20892, (301) 435– 2409, shabestb@csr.nih.gov. Name of Committee: Health of the Population Integrated Review Group, Biostatistical Methods and Research Design Study Section. Date: February 16, 2007. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: George Washington University Inn, 824 New Hampshire Ave., NW., Washington, DC 20037. Contact Person: Ann Hardy, DRPH, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3158, MSC 7770, Bethesda, MD 20892, (301) 435– 0695, hardyan@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Community Level Health Promotion R21, R15, and R03’s. Date: February 16, 2007. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Fungai F. Chanestsa, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3135, MSC 7770, Bethesda, MD 20892, (301) 435– 1262, chanetsaf@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: December 14, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–9797 Filed 12–21–06; 8:45 am] BILLING CODE 4140–01–M PO 00000 Frm 00079 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Method of Treating or Preventing Cancer Using Radiosensitizing Agents National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the invention embodied in U.S. Provisional Patent Application No. 60/718,172, filed September 16, 2005, entitled ‘‘Method of Treating or Preventing Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents’’ [E–319–2005/0–US–01; E–319– 2005/0–PCT–02], to Vion Pharmaceuticals, Inc., having a place of business in New Haven, Connecticut. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to the use of the Triapine as a radiosensitizer as claimed in the licensed patent rights for the treatment of cancer and other tumors. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 20, 2007 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Adaku Madu, J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 5560; Facsimile: (301) 402–0220; E-mail: madua@mail.nih.gov. SUPPLEMENTARY INFORMATION: This technology relates to using 2carboxyaldehyde pyridine thiosemicarbazone compounds or prodrugs thereof, specifically 3-amino2-carboxyaldehyde pyridine thiosemicarbazone (Triapine) or 4methyl-3-amino-2-carbozyaldehyde pyridine thiosemicarbazone, as radiosensitizing agents prior to administering ionizing radiation. E:\FR\FM\22DEN1.SGM 22DEN1 Federal Register / Vol. 71, No. 246 / Friday, December 22, 2006 / Notices The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR Part 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: December 13, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E6–21905 Filed 12–21–06; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY [Docket No. DHS–2006–0074] Homeland Security Advisory Council; Meeting Policy Directorate, Department of Homeland Security. ACTION: Notice of partially closed federal advisory committee meeting. jlentini on PROD1PC65 with NOTICES AGENCY: SUMMARY: The Homeland Security Advisory Council (HSAC) will hold a meeting for purposes of reporting on task force activities examining: (1) The Future of Terrorism; and (2) Improving the Department’s Culture. In addition, the HSAC will receive briefings and hold member deliberations with Secretary Michael Chertoff. This meeting will be partially closed. DATES: Thursday, January 11, 2007. ADDRESSES: The open portion of the meeting will be held at the Hyatt Regency Washington, at 400 New Jersey Avenue, NW., Washington, DC, 20001, in the Congressional Room, Lobby Floor. The closed portions of the meeting will be held in the Thornton Room of the Hyatt Regency Washington, 11th Floor, and in a yet to be determined government building. If you desire to submit written comments, they must be submitted by January 4, 2007. Comments must be identified by DHS–2006–0074 and may VerDate Aug<31>2005 17:45 Dec 21, 2006 Jkt 211001 be submitted by one of the following methods: • Federal e-Rulemaking Portal: https:// www.regulations.gov. Follow the instructions for submitting comments. • E-mail: HSAC@dhs.gov. Please include docket number in the subject line of the message. • Fax: (202) 282–9207. • Mail: Kezia Williams, Homeland Security Advisory Council, Department of Homeland Security, Washington, DC 20528. Instructions: All submissions received must include the words ‘‘Department of Homeland Security’’ and DHS–2006– 0074, the docket number for this action. Comments received will be posted without alteration at https:// www.regulations.gov, including any personal information provided. Docket: For access to the docket to read background documents or comments received by the DHS Homeland Security Advisory Council, go to https://www.regulations.gov. FOR FURTHER INFORMATION CONTACT: Kezia Williams, Homeland Security Advisory Council, Washington, DC 20528, (202) 447–3135, HSAC@dhs.gov. SUPPLEMENTARY INFORMATION: At the upcoming meeting, the HSAC will focus on the future of terrorism; threat assessment/intelligence update, and improving the culture within the Department of Homeland Security. The HSAC will also hold deliberations and discussions among HSAC members, including discussions regarding administrative matters. During the open portion of the meeting, from 11:15 a.m. to 12:30 p.m., the HSAC will consider task force reports on ‘‘The Future of Terrorism’’ and ‘‘Improving the Department’s Culture.’’ The closed portion of the meeting will be held from 9 a.m. to 11:15 a.m., and then again from 12:30 p.m. to 3:30 p.m. It will include discussions on improving the Department’s culture, as well as on the future of terrorism, and how the department should strategically adjust and enhance public preparedness. Schedules permitting, the closed session will include a meeting with a congressional leader. During the closed portions of the meeting, various speakers from the Department and outside will discuss the current trends in terrorism as well as how various companies and organizations have created healthy cultures. Therefore, certain trade secrets are likely to be discussed as well as the manner in which the federal government investigates and tracks the patterns of terrorism. PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 77039 Public Attendance: A limited number of members of the public may register to attend the public session on a firstcome, first-served basis per the procedures that follow. Security requires that any member of the public who wishes to attend the public session provide his or her name and date of birth no later than 5 p.m. e.s.t., Thursday, January 4, 2007, to Kezia Williams or an Executive Staff Member of the HSAC via e-mail at HSAC@dhs.gov or via phone at (202) 447–3135. Photo identification will be required for entry into the public session, and everyone in attendance must be present and seated by 11 a.m. Information on Services for Individuals with Disabilities: For information on facilities or services for individuals with disabilities, or to request special assistance at the meeting, contact Kezia Williams as soon as possible. Basis for Closure: In accordance with Section 10(d) of the Federal Advisory Committee Act, Public Law 92–463, as amended (5 U.S.C. App.), portions of this HSAC meeting will be closed. At the closed portions of the meeting, the committee will be addressing specific security and infrastructure vulnerabilities, and these discussions are likely to include: trade secrets and commercial or financial information that is privileged or confidential; investigative techniques and procedures; and matters that for which disclosure would likely frustrate significantly the implementation of proposed agency actions. Accordingly, these portions of the meeting must be closed as consistent with the provisions of 5 U.S.C. 552b(c)(4), (7)(E), and (9)(B). Stewart Baker, Assistant Secretary for Policy. [FR Doc. E6–21914 Filed 12–21–06; 8:45 am] BILLING CODE 4410–10–P DEPARTMENT OF HOMELAND SECURITY Bureau of Customs and Border Protection [CBP Dec. 06–40] Re-Accreditation and Re-Approval SGS North America, Inc., Deer Park, TX as a Commercial Gauger and Laboratory Bureau of Customs and Border Protection, Department of Homeland Security. ACTION: Notice of re-approval of SGS North America, Inc., of Deer Park, AGENCY: E:\FR\FM\22DEN1.SGM 22DEN1

Agencies

[Federal Register Volume 71, Number 246 (Friday, December 22, 2006)]
[Notices]
[Pages 77038-77039]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-21905]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Method of Treating or 
Preventing Cancer Using Radiosensitizing Agents

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR Part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to practice the invention embodied in U.S. 
Provisional Patent Application No. 60/718,172, filed September 16, 
2005, entitled ``Method of Treating or Preventing Cancer Using Pyridine 
Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents'' [E-
319-2005/0-US-01; E-319-2005/0-PCT-02], to Vion Pharmaceuticals, Inc., 
having a place of business in New Haven, Connecticut. The patent rights 
in these inventions have been assigned to the United States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to the use of the Triapine as a 
radiosensitizer as claimed in the licensed patent rights for the 
treatment of cancer and other tumors.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
February 20, 2007 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Adaku Madu, J.D., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 435-5560; Facsimile: (301) 402-0220; E-mail: 
madua@mail.nih.gov.

SUPPLEMENTARY INFORMATION: This technology relates to using 2-
carboxyaldehyde pyridine thiosemicarbazone compounds or prodrugs 
thereof, specifically 3-amino-2-carboxyaldehyde pyridine 
thiosemicarbazone (Triapine) or 4-methyl-3-amino-2-carbozyaldehyde 
pyridine thiosemicarbazone, as radiosensitizing agents prior to 
administering ionizing radiation.

[[Page 77039]]

    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 
404.7. The prospective exclusive license may be granted unless within 
sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR Part 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: December 13, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E6-21905 Filed 12-21-06; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.